The interdependent influence of lobbying and intellectual capital on new drug development
Year of publication: |
2024
|
---|---|
Authors: | Vrande, Vareska van de ; Subramanian, Annapoornima M. ; Lévesque, Moren ; Klopf, Patricia |
Published in: |
Research policy : policy, management and economic studies of science, technology and innovation. - Amsterdam : Elsevier, ISSN 1873-7625, ZDB-ID 1491698-8. - Vol. 53.2024, 2, Art.-No. 104938, p. 1-16
|
Subject: | Intellectual capital | Lobbying breadth | Lobbying intensity | New drug development | Non-market strategy | Interessenpolitik | Lobbying | Immaterielle Werte | Intangible assets | Pharmaindustrie | Pharmaceutical industry | Arzneimittel | Pharmaceuticals | Pharmakologie | Pharmacology |
-
How can small firms benefit from open innovation? : the case of new drug development in Taiwan
Su, Yu-Shan, (2016)
-
Impact of intellectual capital on innovation in pharmaceutical manufacturing SMEs in Pakistan
Qurashi, Ieeqan A., (2020)
-
Impact of intellectual capital on financial vulnerability of pharmaceuticals sector in Pakistan
Aslam, Shoaib, (2015)
- More ...
-
Are biopharma firms discontinuing doomed drug discovery projects fast eEnough?
Subramanian, Annapoornima M., (2022)
-
Lévesque, Moren, (2023)
-
The role of intellectual capital in new product development : can it become a liability?
Subramanian, Annapoornima M., (2019)
- More ...